Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > ORGANIZATION
ORGANIZATION
- Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
June 27, 2023
- FPMAJ Chief Shows Enthusiasm toward Drug Pricing Reform, Vows to Exchange Views with All Affiliate Groups
June 26, 2023
- New JPMA Director General Keen to Make “Special Price Maintenance” Happen after 15 Years
June 23, 2023
- FPMAJ Makes 1st Update for Generic Supply Guidelines in 9 Years
June 22, 2023
- Patient Group Requests Early Approval of New ALS Drugs in Japan
June 22, 2023
- Astellas’ Yoshitsugu Shitaka Elected as New FIRM Chair
June 20, 2023
- Lag and Loss Blamed on Drug Pricing System, JPMA Set to Get Involved in Corrective Steps: President
June 15, 2023
- Over 70% of Pharmacies Fill “Zero” Refill Prescriptions per Month: FPMAJ Survey
June 13, 2023
- FPMAJ Demands Better Criteria for Selecting Comparator Drugs to Factor in Disease Features and Product Positioning
June 12, 2023
- PMP Company Criteria Mar Market Attractiveness, Scrap Them: FPMAJ
June 12, 2023
- Tide Has Changed, but That Doesn’t Erase Concerns: FPMAJ Drug Pricing Chief
June 12, 2023
- Regenerative Medicine Group Hails Expert Panel’s Proposal on New Pricing Method for Innovative Therapies
June 9, 2023
- JMA Renews Opposition for Health Coverage Review for Pharmaceuticals
June 8, 2023
- Pharma Hails Expert Panel Report, Looks for Govt Leadership to Execute Reforms
June 7, 2023
- Industry’s Concerns Beginning to Sink in among Policymakers: JPMA Committee Chair
June 7, 2023
- Protect Info for Off-Patent Brands Even after Market Exit: JEMA
May 29, 2023
- Eisai’s Yasushi Okada Becomes FPMAJ Chairman
May 26, 2023
- New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
- 12 Medical and Nursing Care Groups Demand Responses to Inflation, Wage Hikes
May 26, 2023
- Mitsubishi Tanabe’s Ueno Elected as New JPMA President
May 26, 2023
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…